Sutro Biopharma (STRO, Financial) has named Greg Chow as its Chief Financial Officer, effective June 2, 2025. Before joining Sutro, Chow held the position of Chief Financial and Business Officer at NodThera, where he was instrumental in driving business development and managing financing operations.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for Sutro Biopharma Inc (STRO, Financial) is $3.26 with a high estimate of $7.00 and a low estimate of $0.80. The average target implies an upside of 262.83% from the current price of $0.90. More detailed estimate data can be found on the Sutro Biopharma Inc (STRO) Forecast page.
Based on the consensus recommendation from 11 brokerage firms, Sutro Biopharma Inc's (STRO, Financial) average brokerage recommendation is currently 2.6, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Sutro Biopharma Inc (STRO, Financial) in one year is $1.96, suggesting a upside of 118.34% from the current price of $0.8977. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Sutro Biopharma Inc (STRO) Summary page.
STRO Key Business Developments
Release Date: March 13, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- Sutro Biopharma Inc (STRO, Financial) has prioritized three wholly owned pre-clinical programs in its next-generation ADC pipeline, indicating a focused strategic direction.
- The company's cash runway has been extended into at least Q4 of 2026, providing financial stability for the near future.
- Sutro Biopharma Inc (STRO) has established external manufacturing partnerships, allowing for scalable production capabilities.
- The company's proprietary technology enables precise design of ADCs, offering unique advantages over conventional methods.
- Sutro Biopharma Inc (STRO) has attracted world-class partners such as Astellas and Ipsen, highlighting the potential and credibility of its platform.
Negative Points
- Sutro Biopharma Inc (STRO) is reducing its workforce by nearly 50%, which may impact employee morale and operational capacity.
- The company has deprioritized the development of Levelta due to limited resources, potentially missing out on its full potential.
- There is a challenging macro environment affecting Sutro Biopharma Inc (STRO)'s ability to advance certain programs independently.
- The decision to externalize manufacturing capabilities may lead to dependency on external partners for production.
- The company faces competition from other firms, such as Pfizer, in the ADC space, which could impact its market position.
